TRIALS

The phase 3 VALOR trial shows that brepocitinib significantly improves skin disease, muscle strength, and functional disability in adults with dermatomyositis. As the first modern targeted therapy to demonstrate positive results, brepocitinib may transform treatment options while reducing steroid reliance.

A 16-week Mediterranean diet program significantly improved psoriasis severity and quality of life, independent of weight loss.

Exercise, not liraglutide, reduced atherosclerosis after weight loss in adults with obesity, improving inflammation and heart health.

Olezarsen cuts triglycerides up to 60%, normalizing levels in 85% of high-risk patients.

Baxdrostat lowers BP in resistant hypertension, offering a new treatment option.

Metabolic syndrome raises Parkinson’s risk by 39%, especially with genetic predisposition.

Oral testosterone undecanoate (Jatenzo) boosted T levels & sexual function in 92% of hypogonadal men by day 105 in phase 3 trial.

  A recent study presented at the Musculoskeletal Infection Society Annual Meeting (Aug. 1–2, 2025, Jersey City, N.J.) highlighted the benefits of implementing a standardized protocol for managing periprosthetic joint …

FDA approves Vizz™—the first once-daily eye drop for presbyopia. Fast onset (30 mins), long-lasting (10 hrs), no myopic shift. Backed by CLARITY trials with 96% near-vision improvement. Designed for active lifestyles.
#EyeHealth #VizzDrop

🧠 A major study shows the MIND diet may cut Alzheimer’s risk by up to 25%, with greatest benefit seen in those improving diet over time. Results vary by ethnicity, highlighting need for culturally adapted plans. #BrainHealth #MINDdiet